m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05694
 [1]
m6A modification MALAT1 MALAT1 METTL3 Methylation : m6A sites Direct Enhancement Non-coding RNA MALAT1 miR-124-3p  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Metastasis associated lung adenocarcinoma transcript 1 (MALAT1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Metastasis associated lung adenocarcinoma transcript 1 (MALAT1) LncRNA View Details
Regulated Target hsa-miR-124-3p View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary ES samples expressed low hsa-miR-124-3p and high METTL3, Metastasis associated lung adenocarcinoma transcript 1 (MALAT1) and CDK4. METTL3 elevated MALAT1 expression by m6A modification. MALAT1 enhanced CDK4 expression by competing with miR-124-3p. In ES cells, METTL3 silencing repressed cell migration and invasion by inhibiting MALAT1. In conclusion, METTL3 promotes tumorigenesis of ES through the MALAT1/miR-124-3p/CDK4 axis.
Responsed Disease Ewing's sarcoma ICD-11: 2B52
 Disease Info 
Cell Process Cell migration
Cell invasion
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2B52: Ewing's sarcoma 6 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name MK-4827 Phase 3 [2]
Synonyms
1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226
    Click to Show/Hide
External Link
CID: 24958200
TTD: D00BMF
DrugBank: DB11793
 Compound Name FANG vaccine Phase 3 [3]
Synonyms
FANG (TN)
    Click to Show/Hide
External Link
TTD: D0Q4NX
 Compound Name Seclidemstat Phase 1 [4]
Synonyms
UNII-TYH386V3WJ; SP-2577; TYH386V3WJ; 1423715-37-0; SP2577; CHEMBL4297641; SCHEMBL14697017; SCHEMBL14697019; EX-A3574; s6722; BS-15371; HY-103713; CS-0039281; Benzoic acid, 3-((4-methyl-1-piperazinyl)sulfonyl)-, (2E)-2-(1-(5-chloro-2-hydroxyphenyl)ethylidene)hydrazide
    Click to Show/Hide
External Link
CID: 135565033
TTD: DCWT40
 Compound Name pbi-shRNA EWS-FLI-Type 1 Phase 1 [5]
External Link
TTD: D31ZLD
 Compound Name TK216 Phase 1 [2]
External Link
TTD: D0HU0A
 Compound Name Ganitumab Clinical trial [6]
External Link
TTD: D0GR6I
References
Ref 1 METTL3-modified lncRNA-MALAT1 regulates the molecular axis of miR-124-3p/CDK4 involved in Ewing's sarcoma. Cell Mol Biol (Noisy-le-grand). 2023 Jun 30;69(6):193-197. doi: 10.14715/cmb/2023.69.6.29.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 4 ClinicalTrials.gov (NCT03600649) Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas. U.S. National Institutes of Health.
Ref 5 ClinicalTrials.gov (NCT02736565) Pbi-shRNA EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma. U.S. National Institutes of Health.
Ref 6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)